drugset / Trial / NCT02777242

Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism

NCT02777242

Phase 2 Completed 66 enrolled Antares Pharma Inc.
NaSingle-groupOpen-labelTreatment

Summary

Evaluation of the safety and tolerability of testosterone enanthate (TE) following a single dose via QuickShot® Testosterone (QST) when administered by intended users in a usability study.

Timeline

Start
2016-06
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Enanthate Small molecule 50 mg Subcutaneous
Subject Testosterone Enanthate Small molecule 75 mg Subcutaneous
Subject Testosterone Enanthate Small molecule 100 mg Subcutaneous

Indications